Methylphenidate fatigue pilot reports improvement in both treatment groups
Methylphenidate was tested alongside standardized activity, but the abstract does not establish an added fatigue benefit over placebo with the same activity.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Both groups reported improved fatigue during this short pilot. Because everyone received standardized physical activity, the study cannot isolate activity's contribution. The abstract reports changes within each arm without a direct fatigue comparison between arms, so it does not establish whether adding methylphenidate provided extra benefit over placebo in these patients.
This was a small pilot with brief follow-up, and some randomized patients were not evaluable. The abstract does not report a between-group estimate for its primary fatigue outcome.
What researchers found
Mean FACIT-F fatigue-score change
Over 14 days, methylphenidate plus activity and placebo plus activity, respectively. Each arm improved from baseline; a between-arm fatigue comparison was not reported.
What the trial measured
The primary measure was the FACIT-F fatigue questionnaire. Other questionnaires addressed fatigue dimensions, anxiety and depression. These measures describe the symptom outcomes studied; the abstract reports no cancer-progression endpoint.
Reading the secondary results
Some additional fatigue and depression measures improved within the methylphenidate group. Those changes do not establish superiority over placebo. Adverse-event differences were not statistically significant, which does not prove equal safety.
The original publication
Managing fatigue with methylphenidate and physical activity during cancer immunotherapy treatment.
Yennurajalingam S, Fellman B, Williams L et al.
Palliat Support Care · 2025
- PubMed ID
- 41423710
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.